Huang Y - Search Results

1

Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation.

Li S, Huang Y, Sun Y, Lu T, Dong Y, Yu S, Zhang X, Hu H. Li S, et al. Among authors: huang y. Int J Pharm. 2024 Sep 30;663:124585. doi: 10.1016/j.ijpharm.2024.124585. Epub 2024 Aug 13. Int J Pharm. 2024. PMID: 39147248

2

Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.

Pang LL, Liao J, Huang YH, Gan JD, Zhuang WT, Lv Y, Liang WT, Zhang L, Fang WF. Pang LL, et al. Among authors: huang yh. Int J Cancer. 2023 Jun 1;152(11):2338-2350. doi: 10.1002/ijc.34426. Epub 2023 Jan 29. Int J Cancer. 2023. PMID: 36631999

3

Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.

Fang W, Huang Y, Gan J, He B, Zhang L. Fang W, et al. Among authors: huang y. J Thorac Oncol. 2020 Mar;15(3):e34-e35. doi: 10.1016/j.jtho.2019.09.086. J Thorac Oncol. 2020. PMID: 32093856 Free article. No abstract available.

4

Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.

Fang W, Huang Y, Gan J, Zheng Q, Zhang L. Fang W, et al. Among authors: huang y. J Thorac Oncol. 2020 Mar;15(3):e36-e37. doi: 10.1016/j.jtho.2019.09.198. J Thorac Oncol. 2020. PMID: 32093857 Free article. No abstract available.

5

Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.

Huang Y, Zhao Y, Huang Y, Yang Y, Zhang Y, Hong S, Zhao H, Zhao S, Zhou T, Chen G, Zhou H, Ma Y, Zhou N, Zhang L, Fang W. Huang Y, et al. MedComm (2020). 2024 Apr 29;5(5):e536. doi: 10.1002/mco2.536. eCollection 2024 May. MedComm (2020). 2024. PMID: 38685972 Free PMC article.

6

Research progress in immune checkpoint inhibitors for lung cancer in China.

Gan J, Huang Y, Fang W, Zhang L. Gan J, et al. Among authors: huang y. Ther Adv Med Oncol. 2021 Jul 20;13:17588359211029826. doi: 10.1177/17588359211029826. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34349843 Free PMC article. Review.

7

Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.

Fang W, Gan J, Huang Y, Zhou H, Zhang L. Fang W, et al. Among authors: huang y. J Thorac Oncol. 2019 Dec;14(12):e274-e275. doi: 10.1016/j.jtho.2019.07.018. J Thorac Oncol. 2019. PMID: 31757379 Free article. No abstract available.

8

A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.

Fang W, Huang Y, Gan J, Hong S, Zhang L. Fang W, et al. Among authors: huang y. J Thorac Oncol. 2019 Sep;14(9):e201-e202. doi: 10.1016/j.jtho.2019.04.013. J Thorac Oncol. 2019. PMID: 31445736 Free article. No abstract available.

9

Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.

Zheng Q, Fang W, Huang Y, Gan J, Zhang L. Zheng Q, et al. Among authors: huang y. J Thorac Oncol. 2020 Aug;15(8):e132-e133. doi: 10.1016/j.jtho.2019.12.114. J Thorac Oncol. 2020. PMID: 32718536 Free article. No abstract available.

10

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.

Gan J, Huang Y, Liao J, Pang L, Fang W. Gan J, et al. Among authors: huang y. Onco Targets Ther. 2021 Nov 18;14:5297-5307. doi: 10.2147/OTT.S335217. eCollection 2021. Onco Targets Ther. 2021. PMID: 34824536 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81,960 results

Search Page

Filters